Beyond Access vs. Protection in Trials of Innovative Therapies

See allHide authors and affiliations

Science  14 May 2010:
Vol. 328, Issue 5980, pp. 829-830
DOI: 10.1126/science.1189369

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Over the past decade, researchers have initiated innovative, early-phase, clinical trials, including the first-ever testing in humans of cell therapies for myocardial infarction (1), as well as transplantation of embryo-derived tissues for spinal cord repair (2). The next decade promises more initiatives involving first-in-human trials of innovative therapeutic strategies (3).